KalVista Pharmaceuticals, Inc. (KALV)
| Previous Close | 10.49 |
| Open | 10.50 |
| Bid | 10.44 x 100 |
| Ask | 10.57 x 200 |
| Day's Range | 10.27 - 10.66 |
| 52 Week Range | 7.21 - 16.88 |
| Volume | |
| Avg. Volume | 823,791 |
| Market Cap | 443.399M |
| Beta (5Y Monthly) | 0.91 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Barrons.com
ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors
RA Capital increased its stake in biopharmaceutical firm ARS. Bain Capital lowered its stake in pharmaceutical firm Nuvalent.
- Reuters
UPDATE 1-KalVista meets main goals in late-stage trial for genetic disease
KalVista Pharmaceuticals said on Tuesday its therapy for a type of genetic condition, which causes rapid swelling under the skin and in other parts of the body, met main goals in a late-stage trial. The therapy, sebetralstat, showed beginning of symptom relief in patients with hereditary angioedema (HAE) significantly faster than placebo. The median time to beginning of symptom relief was 1.61 hours with the lower dose version of sebetralstat and 6.72 hours with placebo.
- GuruFocus.com
Insider Sell: Chief Scientific Officer Edward Feener Sells 22,679 Shares of KalVista ...
KalVista Pharmaceuticals Inc (NASDAQ:KALV), a pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need, has reported an insider sell according to a recent SEC filing.
